A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.


Updates from The Motley Fool

Latest updates on Nektar Therapeutics from Fool.com.  The Fool has written over 100 articles on Nektar Therapeutics.
This Week in Biotech

An EU approval for an HIV therapy enhancing drug, mixed late-stage reviews for another big pharma...



Stock Performance

View Interactive NKTR Charts
Sponsored by

Key Data Points

Primary metrics and data points about Nektar Therapeutics.
Current Price: $23.80
Prev Close: $23.38
Open: $23.35
Bid: $23.69
Ask: $23.70
Day's Range: $23.14 - $24.04
52wk Range: $11.41 - $24.04
Volume: 865,329
Avg Vol 2,442,164
Market Cap: $4B
P/E (ttm): -21.25
EPS (ttm): ($1.10)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Nektar Therapeutics.
CAPS Rating 2 out of 5
 
224 Outperform
35 Underperform
CAPS All Stars
 
48 Outperform
11 Underperform

How do you think Nektar Therapeutics will perform against the market?



You pick for Nektar Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Howard W. Robin, CEO

76% Approve

Based on 32 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Nektar Therapeutics.

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers